MY129008A - Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotheraphy - Google Patents
Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotheraphyInfo
- Publication number
- MY129008A MY129008A MYPI20012470A MY129008A MY 129008 A MY129008 A MY 129008A MY PI20012470 A MYPI20012470 A MY PI20012470A MY 129008 A MY129008 A MY 129008A
- Authority
- MY
- Malaysia
- Prior art keywords
- vip
- radiolabeled
- receptor
- vasoactive intestinal
- agent
- Prior art date
Links
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 title abstract 5
- 238000003745 diagnosis Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 abstract 2
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000012216 imaging agent Substances 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 238000000163 radioactive labelling Methods 0.000 abstract 2
- 230000003439 radiotherapeutic effect Effects 0.000 abstract 2
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 238000012800 visualization Methods 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
THE PRESENT INVENTION ENCOMPASES RADIOLABELED PEPTIDE ANALOGS OF VASOACTIVE INTESTINAL PEPTIDE (VIP) LABELED WITH A RADIONUCLIDE USEFUL FOR IMAGING TARGET SITES WITHIN MAMMALIAN LIVING SYSTEMS. THE INVENTION PARTICULARLY PROVIDES RADIOLABELED VIP DERIVATIVES THAT BIND SELECTIVELY TO THE VIP RECEPTOR ON TARGET CELLS.SPECIFICALLY, THE INVENTION RELATES TO THE RADIOLABELING OF VIP-RECEPTOR SPECIFIC AGENTS AND THEIR SUBSEQUENTS USE FOR RADIODIAGNOSTIC AND RADIOTHERAPEUTIC PURPOSES. THE INVENTION ENCOMPASSES METHODS FOR RADIOLABELING THESE PEPTIDES WITH RADIO-NUCLIDES AND THE USE OF THESE PEPTIDES AS SCINTIGRAPHIC IMAGING AGENTS. THE RADIOLABELED VIP DERIVATIVES OF THE PRESENT INVENTION EXHIBIT PHARMACOLOGICAL ACTIVITY AND THEREFORE ARE USEFUL AS EITHER IMAGING AGENT FOR VISUALIZATION OF VIP-RECEPTOR POSITIVE TUMORS AND MATESTASES, AS A RADIODIAGNOSTIC AGENT OR AS A RADIO- THERAPEUTIC AGENT FOR THE TREATMENT OF SUCH TUMORS IN VIVO BY SPECIFICALLY TARGETING THE CYTOTOXIC RADIONUCLIDE SELECTIVELY TO THE TUMOR SITE IN MAMMALIAN LIVING SYSTEMS.(FIG.1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/629,632 US6608174B1 (en) | 2000-02-18 | 2000-07-31 | Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY129008A true MY129008A (en) | 2007-03-30 |
Family
ID=37515842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20012470 MY129008A (en) | 2000-07-31 | 2001-05-24 | Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotheraphy |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR030223A1 (en) |
| MY (1) | MY129008A (en) |
| TW (1) | TWI288751B (en) |
-
2001
- 2001-05-22 AR ARP010102425A patent/AR030223A1/en not_active Application Discontinuation
- 2001-05-24 MY MYPI20012470 patent/MY129008A/en unknown
- 2001-07-31 TW TW90118678A patent/TWI288751B/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| TWI288751B (en) | 2007-10-21 |
| AR030223A1 (en) | 2003-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Miao et al. | In vivo evaluation of 188Re‐labeled alpha‐melanocyte stimulating hormone peptide analogs for melanoma therapy | |
| Smith et al. | Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN [7-14] NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells | |
| Kiess et al. | Prostate-specific membrane antigen as a target for cancer imaging and therapy | |
| Smith et al. | Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update | |
| Gali et al. | Synthesis, characterization, and labeling with 99mTc/188Re of peptide conjugates containing a dithia-bisphosphine chelating agent | |
| Koumarianou et al. | 44Sc-DOTA-BN [2-14] NH2 in comparison to 68Ga-DOTA-BN [2-14] NH2 in pre-clinical investigation. Is 44Sc a potential radionuclide for PET? | |
| Hoffman et al. | Radiometallated receptor-avid peptide conjugates for specific in vivo targeting of cancer cells | |
| EP3486249B1 (en) | 99mtc-edda/hynic-ipsma as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen | |
| Maina et al. | Targeting prostate cancer with radiolabelled bombesins | |
| MX9707426A (en) | Radiolabeled peptides for diagnosis and therapy. | |
| Sabahnoo et al. | New small 99mTc-labeled peptides for HER2 receptor imaging | |
| Miao et al. | Tumor-targeting properties of 90Y-and 177Lu-labeled α-melanocyte stimulating hormone peptide analogues in a murine melanoma model | |
| Guo et al. | Melanoma targeting property of a Lu-177-labeled lactam bridge-cyclized alpha-MSH peptide | |
| Miao et al. | Reducing renal uptake of 90Y-and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues | |
| Abiraj et al. | Tetraamine‐derived bifunctional chelators for technetium‐99m labelling: Synthesis, bioconjugation and evaluation as targeted SPECT imaging probes for GRP‐receptor‐positive tumours | |
| Craft et al. | In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer | |
| Jiang et al. | 177Lu-labeled RGD-BBN heterodimeric peptide for targeting prostate carcinoma | |
| EP0975373B1 (en) | Radionuclide associated with nucleotide polyphosphate as tumor imaging agents | |
| Maina et al. | [99mTc] Demotensin 5 and 6 in the NTS1-R-targeted imaging of tumours: synthesis and preclinical results | |
| AU2000263935A1 (en) | Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy | |
| Makris et al. | Preclinical evaluation of novel 64Cu-labeled gastrin-releasing peptide receptor bioconjugates for PET imaging of prostate cancer | |
| Hanaoka et al. | Evaluation of 64Cu-labeled DOTA-d-Phe1-Tyr3-octreotide (64Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors | |
| Maina et al. | [99mTc] Demotate 2 in the detection of sst2-positive tumours: a preclinical comparison with [111In] DOTA-tate | |
| Ferro-Flores et al. | Radiolabeled protein-inhibitor peptides with rapid clinical translation towards imaging and therapy | |
| Zheng et al. | Comparison of biological properties of 111In-labeled dimeric cyclic RGD peptides |